IGF-1 Interacted With Obesity in Prognosis Prediction in HER2-Positive Breast Cancer Patients

• Published in: Frontiers in oncology Vol. 10; p. 550
• Main Authors: Tong, Yiwei, Wu, Jiayi, Huang, Ou, He, Jianrong, Zhu, Li, Chen, Weiguo, Li, Yafen, Chen, Xiaosong, Shen, Kunwei
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 24.04.2020
• Subjects: breast cancer; disease outcome; HER2-positive; IGF-1; metabolic syndrome; Oncology; metabolic syndrome; disease outcome; breast cancer; IGF-1; HER2-positive
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2020.00550

Dysmetabolism and high circulating insulin-like growth factor 1 (IGF-1) would increase breast cancer risk, but its association with survival in HER2+ breast cancer patients has not been well-studied. Herein, we aim to evaluate the prognostic value of IGF-1 and metabolic abnormalities in HER2+ population. HER2+ breast cancer patients treated in Ruijin Hospital between November 2012 and June 2017 were retrospectively analyzed. Median value of circulating IGF-1 was adopted to classify low or high IGF-1 group. Metabolic syndrome (MetS) was defined using AHA/NHLBI criteria. Overweight was defined by body mass index (BMI) ≥ 24.0 kg/m in Chinese population. Overall, 679 patients were included and 209 had synchronous MetS. High IGF-1 level was more common in pre/peri-menopausal women ( < 0.001) and high IGFBP-3 patients ( < 0.001). After a median follow-up of 36 months, 52 patients had disease recurrences. IGF-1 level was not associated with recurrence-free survival (RFS, = 0.620) in the whole population. However, exploratory subgroup analysis found that BMI and IGF-1 interacted in predicting RFS ( = 0.009). For non-overweight patients, high IGF-1 showed a superior 4-years RFS (91.1 vs. 85.0%; HR 0.53, 95% CI 0.27-1.00, = 0.049) compared with patients with low IGF-1 level. In contrast, for overweight patients, high IGF-1 was associated with an impaired 4-years RFS (88.3 vs. 95.7%, HR 3.20, 95% CI 1.00-10.21, = 0.038). Furthermore, high IGF-1 level was independently associated with better OS in the whole (HR 0.26, 95% CI 0.08-0.82, = 0.044) as well as non-overweight population (HR 0.15, 95% CI 0.03-0.68, = 0.005). IGF-1 level was not associated with RFS in HER2+ breast cancer patients. However, IGF-1 and BMI had significant interaction in disease outcome prediction in HER2+ patients. High IGF-1 was protective in non-overweight patients, but risk factor for those overweight, which deserves further evaluation.